The #FDA has approved datopotamab deruxtecan (Dato-DXd) for adults with unresectable or metastatic HR+/HER2- #breastcancer after improving PFS and overall survival compared with #chemo in a phase 3 clinical trial.

You can learn more using the link below.
#FDA #breastcancer #chemo